Micot
Latest round
- Series D
Last raised
- Oct 2025
Total raised
- $71M
Investors
- 10
About Micot
, dba Micot, is a biotechnology company specializing in the discovery, development and commercialization of bi-/multi-specific peptide drugs for the treatment of metabolic diseases as well as cardiovascular and cerebrovascular diseases. The company has research and operation center in the United States, and has set up branch offices in Suzhou, Shanghai, and Hong Kong. In 2024 one of the company's pipelines completed Phase III trials. In January 2025, the company was converted into a joint stock company.2 apiece on the Hong Kong Exchanges and Clearing (HKEX) under the ticker "2335". Micot focuses on the research and development of novel molecular drugs for bi-functional and multifunctional specific peptides, having developed multiple candidate drugs for metabolic and cardiovascular and cerebrovascular diseases. The company's core product, MT1013, is the dual-targeting receptor agonist polypeptide that simultaneously targets the CaSR (Calcium-Sensing Receptor) and the OGP (Osteogenic Growth Peptide) receptor, designed for the treatment of CKD-SHPT (Chronic Kidney Disease-induced Secondary Hyperparathyroidism), CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder) with Osteoporosis and CKD-SHPT not on Dialysis. Micot generates revenue by developing peptide drugs, adopting dual-track commercialization approach: domestically through collaborations with third party Contract Sales Organizations (CSOs) and internationally via license-out partnerships. Following the IPO on HKEX in June 2026, Micot plans to accelerate the clinical development of its core product and key product candidates, continue to focus on major disease areas such as metabolic disorders (particularly renal-related) and cardiovascular and cerebrovascular diseases to develop differentiated treatment solutions with differentiated advantages, deepen strategic collaborations with industry participants both domestically and overseas, and recruit and retain talents to promote systematic training and sustainable development.
Who invested in Micot
10 investors across 3 rounds
See all investors in Micot
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Micot
Who invested in Micot?
Micot has 10 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Micot raised?
Micot has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Micot last raise money?
Micot's most recent round on record is a Series D, in Oct 2025.
What does Micot do?
, dba Micot, is a biotechnology company specializing in the discovery, development and commercialization of bi-/multi-specific peptide drugs for the treatment of metabolic diseases as well as cardiovascular and cerebrovascular diseases.
Where is Micot headquartered?
Micot is headquartered in Xi'an, China.
Which VCs invest in companies like Micot?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Micot's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series D
Raising like Micot? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.